Advisor Group Holdings, Inc. Jounce Therapeutics, Inc. Transaction History

Advisor Group Holdings, Inc.

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 12, 2023	BUY	$0.9 - $1.85 $990 - $2,035	1,100 Added 88.0%	2,350 $4,000
Q4 2022 Feb 10, 2023	BUY	$0.64 - $1.99 $736 - $2,288	1,150 Added 1150.0%	1,250 $1,000
Q2 2022 Aug 10, 2022	SELL	$2.8 - $7.67 $89 - $245	-32 Reduced 24.24%	100 $0
Q1 2022 May 04, 2022	BUY	$6.01 - $8.54 $192 - $273	32 Added 32.0%	132 $1,000
Q1 2021 May 13, 2021	SELL	$6.73 - $13.87 $65,947 - $135,912	-9,799 Reduced 98.99%	100 $1,000
Q4 2020 Feb 10, 2021	BUY	$6.37 - $10.33 $18,759 - $30,421	2,945 Added 42.35%	9,899 $69,000
Q3 2020 Nov 12, 2020	BUY	$4.58 - $10.95 $439 - $1,051	96 Added 1.4%	6,954 $49,000
Q2 2020 Aug 14, 2020	BUY	$4.17 - $7.58 $9,082 - $16,509	2,178 Added 46.54%	6,858 $47,000
Q1 2020 May 18, 2020	BUY	$2.91 - $8.7 $13,618 - $40,716	4,680 New	4,680 $23,000

720K

Ticker JNCE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 51,694,200
Description
Jounce Therapeutics, Inc., a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The company develops vopratelimab, a clinical-stage monoclonal antibody, which is in Phase II clinical trial that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid ...

Get notified when there are updates to the investment portfolio of Advisor Group Holdings, Inc., based on Form 13F filings with the SEC.

Stay updated on Advisor Group Holdings, Inc. with notifications on news.